• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降低痴呆风险的健康干预计划的成本效益:瑞典/芬兰环境下的马尔可夫模型结果。

Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting.

机构信息

Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.

出版信息

J Alzheimers Dis. 2011;26(4):735-44. doi: 10.3233/JAD-2011-110065.

DOI:10.3233/JAD-2011-110065
PMID:21709377
Abstract

Risk scores based on modifiable factors have recently been developed for dementia. This study aims to estimate the cost-effectiveness of a potential preventive intervention program meant to lower the score related to increased dementia risk. Analyses were based on a Markov model adapted to Swedish circumstances. Risk score categories and risk probabilities were derived from the Cardiovascular Risk Factors, Aging and Incidence of Dementia (CAIDE) study in Finland. Figures of costs, utilities, and mortality were obtained from literature or databases. One-way sensitivity analysis and probabilistic sensitivity analysis were carried out to investigate the robustness of the model and to identify which model inputs had most impact on the results. In the base case, the usual care had a cost of 621,000 SEK and utilities of 11.8438 quality-adjusted life year (QALYs). The intervention had a cost of 599, 026 SEK and utilities of 11.8950 QALYs. The cost was 21,974 SEK lower in the intervention with 0.0511 QALYs gained over a 20 years horizon, indicating absolute dominance. The support for cost-effectiveness was insensitive to changes in the value of QALY for demented, mortality, and risk of dementia. If the intervention program was assumed to run every year, the incremental cost-effectiveness ratio did not show absolute dominance but was still under the willingness-to-pay level. The probabilistic sensitivity analysis indicated cost effectiveness in 67% of the samplings given a willingness-to-pay level of 600,000 SEK/year. This is a promising outlook for future research on preventive interventions in dementia, emphasizing the need of conducting multi-domain randomized trials.

摘要

基于可改变因素的风险评分最近已被开发用于痴呆症。本研究旨在评估一项旨在降低与痴呆风险增加相关评分的潜在预防干预计划的成本效益。分析基于适用于瑞典情况的马尔可夫模型。风险评分类别和风险概率源自芬兰心血管风险因素、衰老和痴呆症发生率(CAIDE)研究。成本、效用和死亡率数据来自文献或数据库。进行了单因素敏感性分析和概率敏感性分析,以考察模型的稳健性,并确定对结果影响最大的模型输入。在基础情况下,常规护理的成本为 621,000 瑞典克朗,效用为 11.8438 个质量调整生命年(QALY)。干预的成本为 599,026 瑞典克朗,效用为 11.8950 QALY。干预组的成本降低了 21,974 瑞典克朗,在 20 年的时间内增加了 0.0511 个 QALY,表明具有绝对优势。在考虑到痴呆患者的 QALY 值、死亡率和痴呆风险的变化时,对成本效益的支持是不敏感的。如果假设干预计划每年进行一次,增量成本效益比虽然不具有绝对优势,但仍低于支付意愿水平。概率敏感性分析表明,在支付意愿水平为 600,000 瑞典克朗/年的情况下,该方案在 67%的抽样中具有成本效益。这为未来针对痴呆症的预防干预措施的研究提供了一个有希望的前景,强调了进行多领域随机试验的必要性。

相似文献

1
Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting.降低痴呆风险的健康干预计划的成本效益:瑞典/芬兰环境下的马尔可夫模型结果。
J Alzheimers Dis. 2011;26(4):735-44. doi: 10.3233/JAD-2011-110065.
2
Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.韩国心血管健康干预个体化微观模拟模型评估韩国人群进行心血管疾病一级预防应用他汀类药物治疗的成本效果分析结果
Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8. doi: 10.1016/j.clinthera.2009.12.013.
3
Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.在瑞典,(高危)动脉粥样硬化患者中氯吡格雷与阿司匹林用于二级预防缺血事件的成本和后果:基于 CAPRIE 试验和高危 CAPRIE 亚组的终生模型。
Appl Health Econ Health Policy. 2010;8(4):251-65. doi: 10.2165/11535520-000000000-00000.
4
Early assessment of the likely cost-effectiveness of a new technology: A Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement.新技术潜在成本效益的早期评估:计算机辅助全膝关节置换术的马尔可夫模型及概率敏感性分析
Int J Technol Assess Health Care. 2006 Spring;22(2):191-202. doi: 10.1017/S0266462306051014.
5
Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.美金刚在瑞典治疗中重度阿尔茨海默病的成本效益分析
Am J Geriatr Pharmacother. 2005 Jun;3(2):77-86. doi: 10.1016/j.amjopharm.2005.05.002.
6
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.他莫昔芬辅助治疗5年后,来曲唑延长辅助治疗对绝经后早期乳腺癌女性的成本效益分析。
Am J Manag Care. 2006 Jul;12(7):374-86.
7
The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.在意大利,缬沙坦治疗慢性心力衰竭的成本效益和成本效用:概率马尔可夫模型。
Am J Cardiovasc Drugs. 2009;9(6):383-92. doi: 10.2165/11315730-000000000-00000.
8
The cost-effectiveness of Maze procedures using ablation techniques at the time of mitral valve surgery.二尖瓣手术时应用消融技术行迷宫手术的成本效益。
Int J Technol Assess Health Care. 2009 Oct;25(4):485-96. doi: 10.1017/S0266462309990511. Epub 2009 Oct 12.
9
Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.澳大利亚背景下低剂量螺旋CT(计算机断层扫描)筛查肺癌的成本效益分析。
Lung Cancer. 2005 May;48(2):171-85. doi: 10.1016/j.lungcan.2004.11.001. Epub 2005 Jan 4.
10
Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.抗环瓜氨酸肽自身抗体检测在类风湿关节炎早期诊断中的成本效益
Ann Rheum Dis. 2008 Oct;67(10):1399-405. doi: 10.1136/ard.2007.077792. Epub 2008 Jan 11.

引用本文的文献

1
Agile Implementation of a Digital Cognitive Assessment for Dementia in Primary Care.基层医疗中痴呆数字认知评估的敏捷实施
Ann Fam Med. 2025 May 27;23(3):199-206. doi: 10.1370/afm.240294.
2
Cost-Effectiveness of the Tailored Activity Programme for Person With Dementia-Caregiver Dyads: A Markov Model.针对痴呆症患者-照顾者二元组的定制活动计划的成本效益:一个马尔可夫模型。
Int J Geriatr Psychiatry. 2025 Feb;40(2):e70049. doi: 10.1002/gps.70049.
3
The impact of hypertension prevention and modification on dementia burden: A systematic review of economic studies.
高血压预防与改善对痴呆负担的影响:经济研究的系统评价
J Prev Alzheimers Dis. 2025 Jan;12(1):100017. doi: 10.1016/j.tjpad.2024.100017. Epub 2025 Jan 1.
4
Cost-effectiveness of a multicomponent intervention against cognitive decline.针对认知衰退的多成分干预措施的成本效益
Alzheimers Dement (N Y). 2025 Jan 3;11(1):e70028. doi: 10.1002/trc2.70028. eCollection 2025 Jan-Mar.
5
Association Between Cognition, Health Related Quality of Life, and Costs in a Population at Risk for Cognitive Decline.认知、健康相关生活质量与认知下降风险人群的成本之间的关联。
J Alzheimers Dis. 2022;89(2):623-632. doi: 10.3233/JAD-215304.
6
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT).三种阿尔茨海默病预防策略的成本效益:来自多领域阿尔茨海默病预防试验(MAPT)的结果。
J Prev Alzheimers Dis. 2021;8(4):425-435. doi: 10.14283/jpad.2021.47.
7
Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions.量化和描述阿尔茨海默病的自然史和成本,以及假设干预的效果。
J Alzheimers Dis. 2020;75(3):891-902. doi: 10.3233/JAD-191055.
8
Face-to-Face and Digital Multidomain Lifestyle Interventions to Enhance Cognitive Reserve and Reduce Risk of Alzheimer's Disease and Related Dementias: A Review of Completed and Prospective Studies.面对面和数字化多领域生活方式干预以增强认知储备和降低阿尔茨海默病及相关痴呆风险:已完成和前瞻性研究综述。
Nutrients. 2019 Sep 19;11(9):2258. doi: 10.3390/nu11092258.
9
Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders.冰山一角:评估阿尔茨海默病和相关痴呆症的全球社会经济成本及其对利益相关者的战略意义。
J Alzheimers Dis. 2019;70(2):323-341. doi: 10.3233/JAD-190426.
10
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.阿尔茨海默病干预措施成本效用分析中的家庭和照护者溢出效应。
Pharmacoeconomics. 2019 Apr;37(4):597-608. doi: 10.1007/s40273-019-00788-3.